FindTrial
Sign In

Using GGT/platelet ratio for assessment of liver function and comparing it with Fibroscan study

The Gamma-glutamyl transpeptidase to platelet ratio for non invasive assessment of liver fibrosis in patients with chronic Hepatitis B,Hepatitis C and non alcoholic fatty liver disease - NIL

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2023/11/059369
Enrollment
150
Registered
2023-11-01
Start date
Unknown
Completion date
Unknown
Last updated
2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K70-K77- Diseases of liver Health Condition 2: K00-K95- Diseases of the digestive system

Interventions

Intervention1: NIL: NIL Control Intervention1: NIL: NIL

Sponsors

Dr Eshan Taneja
Lead Sponsor
Dr B A Shastry
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: Patients at risk of parenchymal liver disease undergoing Fibroscan as part of standard of care With main focus on known etiology of NAFLD ,Hepatitis B ,Hepatitis C who are able to give written informed consent

Exclusion criteria

Exclusion criteria: DERRANGED PLATELET COUNT ( 3,50,000) Known case of cholestasis Alcoholic Liver Disease ( 40-80 g/day of alcohol consumption in me and >20g/day in women) Patient with Cardiac Pacemaker Technical difficulty (Ascites, Pregnancy)

Design outcomes

Primary

MeasureTime frame
To calculate the GGT/Platelet ratio in patients with chronic hepatitis B,C and non-alcoholic fatty liver disease Timepoint: At presentation (baseline)—

Secondary

MeasureTime frame
To compare the GGT/Platelet ratio with grade of fibrosis found on Fibroscan & with AST/ALT RatioTimepoint: At presentation (baseline)—

Countries

India

Contacts

Public ContactDr B A Shastry

Kasturba Medical College , MAHE

shastryba@yahoo.co.in9845702450

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026